On the 23rd of May, 2026, a crowd set fire to the Mongbwalu Clinic, a treatment tent in northern Democratic Republic of the Congo (DRC). In the panic that followed, eighteen individuals who were being treated for Ebola scattered into a local community — a detrimental turn to the facility's very purpose of disease containment. The event followed a trend of similar attacks the days before, sparked by outrage at the government's sanitary burial protocols, which clashed with local customs, as well as public misinformation on the disease, and a negative regard towards such Ebola care centers as places for late-stage patients to die, rather than to receive treatment.

This marked a drastic response to the country's attempts at containing and treating what had, shortly after one month of official declaration on May 15, become the fastest-growing case of Ebola disease. While Ebola, caused by a type of viral infection that arises from orthoebolaviruses, has long been eradicated in most countries, it remains a pressing issue in the DRC, where the outbreak has reached over 1,000 (1,094) cases, with 277 confirmed deaths, as of June 24. With a mortality rate of approximately 25% among patients with the variant, several have been isolated to locations such as field hospitals by organizations such as Doctors Without Borders. However, existing violence by regional militia groups, widespread government distrust, and the remote location and poor infrastructure of afflicted provinces, North Kivu and Ituri, are among the challenges contributing to the difficulty in tracing and treating cases; in fact, these factors have worsened the issue by furthering the undetected spread.

As of now, there is currently no vaccine for the specific strain of Ebola, the Bundibugyo variant, though international attention has fueled developments by the Coalition for Epidemic Preparedness Innovation, which has pledged 60 million dollars towards vaccine development, not unlike concurrent efforts by EVERBO, the University of Oxford, and Moderna.

Meanwhile, on the ground, the Bundibugyo variant has spread across loose national borders into Uganda, adding 20 additional cases and two deaths to the fatally rising figures.

This ongoing epidemic tells a greater story about the dependence of reliable detection and medical response on regional and political stability, and the need for healthcare systems that work with the people towards improved outcomes.

Background and Introduction

In 1692, French physician Guy Patin was said to have reported a woman who "turned to wood," with gradual bone growth in place of muscle. Occurring in about one out of every two million people, Fibrodysplasia Ossificans Progressiva (FOP), commonly known as Stoneman Syndrome, is a rare genetic disorder marked by abnormal bone development and heterotopic ossification (HO) - ectopic bone development where it otherwise should not be - in extraskeletal soft tissue.

This results in a shortening of life and often quality of life due to progressive impairment or even loss of mobility as the ectopic bone continues to spread throughout the body. In 2006, a study by Shore et al. found the cause of FOP to be a random, autosomal dominant mutation in the ACVR1 gene. Under normal circumstances, it is responsible for producing bone morphogenic protein BMI type I receptors: proteins that manage the growth and development of bone and muscles, including facilitating normal, controlled ossification.

Mutations in the ACVR1 gene impair regulators of the receptor's activity, resulting in excessive and uncontrolled activity. This produces an overgrowth of bone and cartilage formation, as well as unregulated ossification that together produce the symptoms associated with FOP. Today, there are approximately 800 living cases of FOP, with intergenerational cases being extremely rare.

Symptoms and Diagnosis

The most common features leading up to diagnosis of FOP include malformed, swollen toes and progressive heterotopic endochondral ossification. Symptoms generally manifest at a young age in the form of noticeable abnormal bone growth in the neck and shoulders, before progressing into the body and the limbs. Detection can emerge around a decade into a person's life and can be painless at first, but often presents long-term challenges for the patient, including eventual malnutrition due to difficulties with eating caused by limited mouth mobility.

Breathing difficulties are common due to ectopic bone formation around the rib cage and restricted lung expansion. As FOP continues to progress in more extreme cases, patients would likely suffer from the inability to walk and perform basic tasks due to a loss of motor control. Patients live a median of 50-60 years, and can express stable forms of the condition, though they often experience sensitivity to external trauma, which can result in reactivation of a more latent form or cause significant flare-ups.

In several cases, surgery for counteracting FOP can be extremely risky, as attempting to remove the ectopic bone can result in stimulated ossification starting at the sites of excision. In addition to clinical evaluations, an FOP diagnosis can be confirmed by genetic testing to detect the mutation of the ACVR1 gene and next-generation genetic sequencing. Other forms of diagnosis include imaging through X-rays and advanced 3D-enhanced CT scans, with the potential of focused biomarkers for early detection in the future.

Current Treatments and Future Research Challenges

Despite research on FOP developing for centuries, the physiological understanding of the condition remains shallow due to the genetic complexity and rarity in numbers. As of today, there are no broadly effective medical treatment options for heterotopic ossification significant to FOP. In 2024, however, the first approved targeted treatment method became available in the US, Canada, Australia, and the UAE: a drug called palovarotene, which was found to limit bone accrual by 60% compared to those without intervention.

While a promising solution, palovarotene comes with several costs and concerns. Beyond limited accessibility, financial burdens, and existing data constraints, palovarotene is currently discouraged from usage by young children due to potential complications - meaning the drug is unable to target FOP in early onset, with childhood being a critical point in disease development. There is a great need for research in finding viable solutions for the critical stages of young patients, as well as methods to counteract existing ectopic bone growth actively.

Other challenges and considerations for the future of FOP research prompt greater awareness and recognition by pharmaceutical companies and medical institutions. As there is no centralized treatment for FOP and there are few cases worldwide, it would be difficult to orchestrate future targeted clinical trials on a wide scale. Still, clinical development and trials of other drugs to counteract variations in the ACVR1 gene are underway. Currently, there are medications to reduce inflammation and flare-ups, while physical and occupational therapy, along with mobility aids, can significantly improve quality of life for affected patients.

Every small step of focused awareness, research, and dedication can make a difference towards helping patients worldwide manage the life-altering effects of FOP.